Sunho Biologics,Inc. (2898) AI Stock Analysis

• Market Cap: HK$971.95M
• Dividend Yield: N/A
• Average Volume (3M): 9.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 130
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 156,666,800
• 10 Day Avg. Volume: 6,180
• 30 Day Avg. Volume: 9,773
• PEG Ratio: 0.10
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 11985.90
• P/FCF Ratio: -2.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: HK$6.00 ▼(-8.95% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is weighed down primarily by severe financial weakness (sharp revenue decline, large losses, and negative cash flows). Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Low leverage

Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.

Early free cash flow improvement

A modest uptick in free cash flow growth, even from a weak base, indicates the business may be beginning to stabilize cash conversion. If sustained, improving FCF can support working capital, fund late-stage development, and reduce dependence on dilutive financing over the medium term.

Access to Hong Kong capital markets

Being listed on HKEX provides structural access to regional and international capital, enhancing options for follow-on financing and strategic partnerships. For a cash‑consuming biotech, this listing bolsters long-term fund-raising flexibility and investor reach versus unlisted peers.

Negative Factors

Severe revenue collapse

A ~98% revenue decline is a structural red flag: it erodes core cash generation, undermines commercial viability, and limits ability to fund operations and R&D internally. Over several months this magnifies funding needs and raises execution risk for product development and commercialization plans.

Deep negative margins and losses

Persistently negative operating and net margins indicate the business is not yet achieving scalable economics. Continued losses deplete equity, necessitate external capital, and can lead to repeated dilution, making it harder to achieve sustainable profitability without structural changes to the model.

Negative cash flow and prior negative equity

Negative operating and free cash flows combined with historical negative equity signal weak solvency and limited balance-sheet resilience. Over the medium term this constrains strategic choices, increases refinancing risk, and can force unfavorable financing or asset sales to bridge funding gaps.

Sunho Biologics,Inc. Business Overview & Revenue Model

Company Description

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and CRC. In addition, its preclinical stage products include IBB0979, an immunocytokine for solid tumors; IBC0966, a clinical stage anti-PD-L1 antibody-signal regulatory protein bifunctional fusion protein for tumor specific immune responses; IBD0333 for tumor cells; IAN0982 for oncology; and ISH0988 and ISH0613 immunosuppressors focused on autoimmune diseases. The company was founded in 2018 and is headquartered in Huzhou, China. Sunho Biologics, Inc. is a subsidiary of Sunho Wisdom Investments Limited.

How the Company Makes Money

Sunho Biologics generates revenue primarily through the development and commercialization of its biologic products. The company monetizes its research and development efforts by entering into licensing agreements with pharmaceutical companies, allowing them to market and sell its biologic therapies. Key revenue streams include product sales from approved therapies, milestone payments from partners upon achieving specific development goals, and royalties on sales of licensed products. Additionally, Sunho Biologics may engage in contract manufacturing services for other biotech firms, providing another source of income. Strategic partnerships with larger pharmaceutical companies enhance its financial stability and provide access to broader markets, further contributing to its earnings.

Sunho Biologics,Inc. Financial Statement Overview

Summary

Very weak fundamentals: revenue collapsed (-98.14% latest year) with deeply negative operating and net margins. Cash flow is negative (operating and free cash flow), and while leverage is low, negative ROE and prior negative equity signal financial instability.

Income Statement

Sunho Biologics, Inc. shows significant challenges in its income statement, with negative net profit margins and declining revenue growth. The company has experienced a drastic decrease in revenue, with a -98.14% growth rate in the latest year. Margins are deeply negative, indicating substantial losses at both the operating and net levels.

Balance Sheet

The balance sheet reflects a relatively low debt-to-equity ratio, suggesting limited leverage, which is a positive aspect. However, the company has negative return on equity and negative equity in previous years, indicating financial instability and potential risk for investors.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a slight improvement in free cash flow growth. The ratios of cash flow to net income are positive, but this is due to the negative net income, which is not a favorable sign. Overall, cash flow remains a concern for the company.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.00K	38.00K	17.53M	1.73M	3.22M
Gross Profit	17.00K	38.00K	138.00K	473.00K	3.22M
EBITDA	-83.09M	-94.95M	-123.37M	-38.11M	-64.21M
Net Income	-82.09M	-79.97M	-132.70M	-51.99M	-70.63M
Balance Sheet
Total Assets	557.88M	560.74M	290.45M	70.86M	84.95M
Cash, Cash Equivalents and Short-Term Investments	441.40M	457.28M	210.07M	1.82M	10.66M
Total Debt	68.24M	41.20M	9.07M	11.03M	160.86M
Total Liabilities	76.62M	48.80M	394.56M	72.36M	216.50M
Stockholders Equity	481.27M	511.94M	-104.11M	-1.50M	-131.55M
Cash Flow
Free Cash Flow	-23.07M	-158.28M	-41.68M	-36.02M	-58.17M
Operating Cash Flow	11.18M	-109.02M	-40.65M	-34.59M	-52.65M
Investing Cash Flow	-417.88M	-345.04M	-83.89M	-1.36M	-10.36M
Financing Cash Flow	-9.63M	406.53M	255.50M	27.10M	64.98M

Sunho Biologics,Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2898, the sentiment is Neutral. The current price of 6.59 is above the 20-day moving average (MA) of 6.33, below the 50-day MA of 6.61, and below the 200-day MA of 6.72, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 48.11 is Neutral, neither overbought nor oversold. The STOCH value of 75.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2898.

Sunho Biologics,Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	73 Outperform	HK$72.52B	16.64	19.62%	―	―	―
2149	63 Neutral	HK$2.58B	10.65	16.76%	―	5.19%	34.68%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
2511	46 Neutral	HK$1.09B	-2.27	-67.27%	―	―	47.42%
2898	41 Neutral	HK$971.95M	-4.74	-15.88%	―	―	―

Sunho Biologics,Inc. Corporate Events

Sunho Biologics Names Executive Director Jiang Xiaoling as New CEO and Chief Scientific Officer

Sunho Biologics, Inc. has appointed executive director Ms. Jiang Xiaoling as both chief executive officer and chief scientific officer, effective 23 January 2026, consolidating top management and R&D leadership roles in a single executive. She will jointly undertake CEO and CSO responsibilities with outgoing executive director Dr. Yin Liusong until his resignation takes effect on 28 February 2026, signalling a managed leadership transition that maintains operational continuity while the company aligns executive duties and remuneration with her experience, responsibilities and prevailing market conditions.

The most recent analyst rating on (HK:2898) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.

Sunho Biologics CEO and Chief Scientific Officer Dr. Yin Liusong to Step Down

Sunho Biologics, Inc. announced that Dr. Yin Liusong has tendered his resignation as executive director, chief executive officer and chief scientific officer, effective 28 February 2026, to pursue other personal and career opportunities. Dr. Yin has indicated there is no disagreement with the board or any matter requiring shareholder attention, and he will continue to perform his duties diligently until his departure to ensure a smooth transition, while the company seeks suitable candidates to fill the CEO and chief scientific officer roles, signaling a significant leadership change that may influence its strategic and scientific direction.

The most recent analyst rating on (HK:2898) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.